FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Alto Neuroscience acquires Chase's treatment-resistant depression drug portfolio for $1.75 million upfront; early data shows strong efficacy for lead candidate ALTO-207.
While ALTO-100's Phase 2 results failed to meet expectations, the company has emphasized the potential of ALTO-300, another MDD treatment currently in Phase 2b trials.
Alto Neuroscience's ALTO-100 Phase 2b study for major depressive disorder failed to meet its primary endpoint, but the company plans further data analysis and studies.
Amer Sports, the maker of Wilson tennis rackets and a host of other sports equipment, raised about $1.37 billion in its initial public offering, which was priced below the previously expected $16-$18 range. This was yet another disappointing IPO.
